KBC Group NV Has $405,000 Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

KBC Group NV increased its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 5.5% in the third quarter, Holdings Channel.com reports. The firm owned 1,213 shares of the company’s stock after purchasing an additional 63 shares during the quarter. KBC Group NV’s holdings in Medpace were worth $405,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. DT Investment Partners LLC bought a new stake in shares of Medpace in the second quarter valued at about $41,000. Ashton Thomas Securities LLC bought a new stake in Medpace in the 3rd quarter valued at approximately $37,000. Ashton Thomas Private Wealth LLC acquired a new position in Medpace during the 2nd quarter worth approximately $52,000. EntryPoint Capital LLC bought a new position in shares of Medpace during the 1st quarter worth approximately $54,000. Finally, Capital Performance Advisors LLP acquired a new stake in shares of Medpace in the third quarter valued at approximately $46,000. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages recently commented on MEDP. Truist Financial reduced their target price on shares of Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. Guggenheim decreased their price objective on Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. Robert W. Baird lowered Medpace from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $413.00 to $349.00 in a report on Wednesday, October 23rd. UBS Group downgraded Medpace from a “buy” rating to a “neutral” rating and decreased their price target for the company from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, William Blair reiterated an “outperform” rating on shares of Medpace in a research note on Tuesday, October 22nd. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $380.00.

Medpace Trading Up 2.0 %

MEDP stock opened at $314.96 on Wednesday. Medpace Holdings, Inc. has a 1-year low of $268.80 and a 1-year high of $459.77. The business’s 50 day simple moving average is $340.90 and its 200 day simple moving average is $374.88. The firm has a market capitalization of $9.79 billion, a PE ratio of 27.05, a PEG ratio of 1.72 and a beta of 1.37.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, October 21st. The company reported $3.01 EPS for the quarter, beating the consensus estimate of $2.77 by $0.24. The firm had revenue of $533.32 million for the quarter, compared to the consensus estimate of $540.99 million. Medpace had a net margin of 17.66% and a return on equity of 50.87%. The company’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the previous year, the company earned $2.22 earnings per share. As a group, sell-side analysts predict that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.